PASG insider transaction filings
Passage BIO, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-29. Screen PASG transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 1 Form 4 filing. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing by 2 insiders — 50,055 shares, $206,101 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 50,055 shares @ $4.12 ($206,101) by Lynx1 Capital Management LP, filed 2026-06-29.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Lynx1 Capital Management LP — 10% owner & Nichols Weston — 10% owner | 1 | 1 leg · 50,055 sh · $206,101 | — | — |
Recent Form 4 filings — Passage BIO, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-29 | 4 | Lynx1 Capital Management LP — 10% owner Nichols Weston — 10% owner | Purchase (P): 50,055 @ $4.12 | EDGAR |
| 2026-05-21 | 4 | Sondhi Dolan — Director | Grant/award (A): 10,539 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Porter Derrell — Director | Grant/award (A): 10,539 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Kapadia Sandip — Director | Grant/award (A): 10,539 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Countouriotis Athena — Director | Grant/award (A): 10,539 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Kassberg Thomas Richard — Director | Grant/award (A): 10,539 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | GOWEN MAXINE — Director | Grant/award (A): 10,539 (derivative) @ $0 | EDGAR |
| 2026-03-18 | 4 | Borthwick Kathleen — CFO | Grant/award (A): 15,610 (derivative) @ $0 | EDGAR |
| 2026-03-18 | 4 | Chou William — PRESIDENT AND CEO, Director | Grant/award (A): 58,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | Borthwick Kathleen — CFO | Option exercise (M): 5,000 · Sale (S): 2,062 @ $18.44 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | Chou William — PRESIDENT AND CEO, Director | Option exercise (M): 10,000 · Sale (S): 4,076 @ $18.44 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Borthwick Kathleen — CFO | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Chou William — PRESIDENT AND CEO, Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-09-15 | 4 | Lynx1 Capital Management LP — 10% owner Nichols Weston — 10% owner | Purchase (P): 325 @ $6.96 · Purchase (P): 19,783 @ $6.99 · Purchase (P): 11,900 @ $6.99 | EDGAR |
| 2025-07-24 | 4 | Lynx1 Capital Management LP — 10% owner Nichols Weston — 10% owner | Purchase (P): 13,123 @ $5.44 · Purchase (P): 49,302 @ $5.74 · Purchase (P): 66,423 @ $5.71 | EDGAR |
| 2025-06-26 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP VII LLC — 10% owner | Sale (S): 231,600 @ $0.35 · Sale (S): 138,800 @ $0.33 · Sale (S): 213,257 @ $0.33 | EDGAR |
| 2025-05-30 | 4 | Sondhi Dolan — Director | Grant/award (A): 201,857 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Porter Derrell — Director | Grant/award (A): 201,857 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Kapadia Sandip — Director | Grant/award (A): 201,857 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Islam Saqib — Director | Grant/award (A): 201,857 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Countouriotis Athena — Director | Grant/award (A): 201,857 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Kassberg Thomas Richard — Director | Grant/award (A): 143,789 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | GOWEN MAXINE — Director | Grant/award (A): 201,857 (derivative) @ $0 | EDGAR |
| 2025-04-24 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP VII LLC — 10% owner | Sale (S): 78,049 @ $0.34 · Sale (S): 89,328 @ $0.34 · Sale (S): 68,195 @ $0.32 | EDGAR |
| 2025-04-17 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP VII LLC — 10% owner | Sale (S): 10,326 @ $0.38 · Sale (S): 61,638 @ $0.33 · Sale (S): 77,090 @ $0.33 | EDGAR |
| 2025-03-18 | 4 | Borthwick Kathleen — CFO | Grant/award (A): 278,386 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Chou William — PRESIDENT AND CEO, Director | Grant/award (A): 779,533 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Cale Edgar B. — GC & CORPORATE SECRETARY | Grant/award (A): 278,386 (derivative) @ $0 | EDGAR |
| 2025-02-12 | 4 | Borthwick Kathleen — CFO | Option exercise (M): 8,000 · Sale (S): 3,183 @ $0.53 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2025-01-14 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP VII LLC — 10% owner | Sale (S): 126,209 @ $0.66 · Sale (S): 17,986 @ $0.64 · Sale (S): 79,024 @ $0.60 | EDGAR |
| 2025-01-08 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP VII LLC — 10% owner | Sale (S): 19,481 @ $0.77 · Sale (S): 52,536 @ $0.71 · Sale (S): 75,007 @ $0.68 | EDGAR |
| 2024-12-31 | 4 | Lynx1 Capital Management LP — 10% owner Nichols Weston — 10% owner | Purchase (P): 373,645 @ $0.65 | EDGAR |
| 2024-12-26 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP VII LLC — 10% owner | Sale (S): 230,321 @ $0.60 | EDGAR |
| 2024-12-11 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP VII LLC — 10% owner | Sale (S): 54,181 @ $0.84 · Sale (S): 8,015 @ $0.80 · Sale (S): 80 @ $0.80 | EDGAR |
| 2024-12-06 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP VII LLC — 10% owner | Sale (S): 76,200 @ $0.79 · Sale (S): 20,903 @ $0.82 | EDGAR |
| 2024-11-27 | 4 | Lynx1 Capital Management LP — 10% owner Nichols Weston — 10% owner | Purchase (P): 259,998 @ $0.56 · Purchase (P): 167,055 @ $0.71 · Purchase (P): 29,300 @ $0.67 | EDGAR |
| 2024-10-02 | 4 | Cale Edgar B. — GC & CORPORATE SECRETARY | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | Kassberg Thomas Richard — Director | Grant/award (A): 174,139 (derivative) @ $0 | EDGAR |
| 2024-09-23 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP VII LLC — 10% owner | Sale (S): 39,300 @ $0.71 | EDGAR |
| 2024-09-18 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP VII LLC — 10% owner | Sale (S): 63,100 @ $0.74 · Sale (S): 111,400 @ $0.73 · Sale (S): 25,631 @ $0.73 | EDGAR |
| 2024-05-23 | 4 | Sondhi Dolan — Director | Grant/award (A): 39,092 (derivative) @ $0 | EDGAR |
| 2024-05-23 | 4 | Porter Derrell — Director | Grant/award (A): 47,693 (derivative) @ $0 | EDGAR |
| 2024-05-23 | 4 | Kapadia Sandip — Director | Grant/award (A): 47,693 (derivative) @ $0 | EDGAR |
| 2024-05-23 | 4 | Islam Saqib — Director | Grant/award (A): 47,693 (derivative) @ $0 | EDGAR |
| 2024-05-23 | 4 | Countouriotis Athena — Director | Grant/award (A): 47,693 (derivative) @ $0 | EDGAR |
| 2024-05-23 | 4 | GOWEN MAXINE — Director | Grant/award (A): 47,693 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Borthwick Kathleen — CFO | Grant/award (A): 227,000 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Forman Mark S — CHIEF MEDICAL OFFICER | Grant/award (A): 203,000 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Chou William — PRESIDENT AND CEO, Director | Grant/award (A): 575,000 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Cale Edgar B. — GC & CORPORATE SECRETARY | Grant/award (A): 203,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Passage BIO, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-27 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-05-26 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-04-28 | 8-K | ? | EDGAR |
| 2026-04-20 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-10 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-03-03 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PASG returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →